Akari CEO abruptly resigns as a special committee moves a PhII patient success into the fail column
Akari Therapeutics CEO Gur Roshwalb is out.
The biotech reported after the market closed on Tuesday that Roshwalb had resigned — effective immediately — after the board decided to set up a special committee to examine the circumstances around an Edison Investment Research report on its rival therapy to Alexion’s Soliris that was suddenly retracted shortly after its release.
The report was retracted due to “material inaccuracies.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
